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ABSTRACT
Objective To determine the effect of fibre,
antispasmodics, and peppermint oil in the treatment of
irritable bowel syndrome.
Design Systematic review and meta-analysis of
randomised controlled trials.
Data sources Medline, Embase, and the Cochrane
controlled trials register up to April 2008.
Review methodsRandomisedcontrolled trialscomparing
fibre,antispasmodics,andpeppermintoilwithplaceboor
notreatmentinadultswithirritablebowelsyndromewere
eligible for inclusion. The minimum duration of therapy
consideredwasoneweek,andstudieshadtoreporteither
aglobalassessmentofcureorimprovementinsymptoms,
or cure of or improvement in abdominal pain, after
treatment.A randomeffects model was used to pooldata
on symptoms, and the effect of therapy compared with
placebo or no treatment was reported as the relative risk
(95% confidence interval) of symptoms persisting.
Results 12 studies compared fibre with placebo or no
treatment in 591 patients (relative risk of persistent
symptoms 0.87, 95% confidence interval 0.76 to 1.00).
This effect was limited to ispaghula (0.78, 0.63 to 0.96).
Twentytwotrialscomparedantispasmodicswithplacebo
in 1778 patients (0.68, 0.57 to 0.81). Various
antispasmodics were studied, but otilonium (four trials,
435 patients, relative risk of persistent symptoms 0.55,
0.31 to 0.97) and hyoscine (three trials, 426 patients,
0.63, 0.51 to 0.78) showed consistent evidence of
efficacy.Fourtrialscomparedpeppermintoilwithplacebo
in 392 patients (0.43, 0.32 to 0.59).
Conclusion Fibre, antispasmodics, and peppermint oil
were all more effective than placebo in the treatment of
irritable bowel syndrome.
INTRODUCTION
Irritable bowel syndrome is a functional gastro-
intestinal disorder characterised by abdominal pain
or discomfort and accompanied by a change in bowel
habit.
1 The condition has a population prevalence of
between 5% and 20% in community surveys.
2-4 No
known structural or anatomical explanation accounts
for the pathophysiology of irritable bowel syndrome,
and the exact cause remains unknown, although
several mechanisms have been proposed. Altered
gastrointestinal motility may contribute to the change
in bowel habit reported by some patients,
5 and a
combination of smooth muscle spasm, visceral hyper-
sensitivity, and abnormalities of central pain proces-
singmayexplaintheabdominalpainthatisanessential
part of the symptom complex.
67
Irritable bowel syndrome is a chronic relapsing and
remitting condition,
89 and a significant proportion of
patients will consult their general practitioner with
symptoms.
910Current guidelines for the management
of irritable bowel syndrome in the United Kingdom
recommend that the diagnosis should be made on
clinical grounds alone, without the need for invasive
investigations, unless alarm symptoms such as rectal
bleeding or weight loss are present.
1112 As a result
general practitioners are increasingly responsible for
the initial management of patients with irritable bowel
syndrome and are expected to refer only a minority to
secondary care.
If they are to fulfil this role effectively, general
practitioners need efficacious treatments that do not
require monitoring and are cheap, safe, and readily
available. This is particularly relevant at the present
time as newer and more expensive drugs have either
failed to show efficacy or been withdrawn from the
market owing to concerns about serious adverse
events. Traditionally, people with irritable bowel
syndromewereinstructedtoincreasetheirdailyintake
of dietary fibre, because of its potentially beneficial
effects on intestinal transit time.
13 When this failed,
various types of smooth muscle relaxants and anti-
spasmodics were used in an attempt to ameliorate
symptoms, particularly pain and bloating.
12 More
recently, peppermint oil, which has been shown to
have antispasmodic properties,
14 has been available
over the counter and has been used in the treatment of
irritable bowel syndrome.
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treatmentofirritablebowelsyndromeiscontroversial.
Results of randomised controlled trials are conflicting,
and many have been underpowered to detect a
difference between active treatment and control inter-
vention.Systematicreviewshavealsocometodifferent
conclusionsabouttheefficacyofthethreetreatmentsin
irritable bowel syndrome.
15-22 As a result confusion
exists as to the roles of these agents, with current
management guidelines for irritable bowel syndrome
making varying recommendations.
11122324
We carried out a systematic review and meta-
analysis to determine the effect of fibre, anti-
spasmodics, and peppermint oil in the treatment of
irritable bowel syndrome.
METHODS
We searched the medical literature using Medline
(1950toApril2008),Embase(1980toApril2008),and
the Cochrane controlled trials register (2007). We
considered randomised controlled trials of adults
(>16 years) with a diagnosis of irritable bowel
syndrome based on a clinician’s opinion or that met
specific diagnostic criteria (Manning, Kruis score,
Rome I, II, or III), combined with the results of
investigations to exclude organic disease if trial
investigators thought this necessary. The studies had
to compare fibre, antispasmodics, and peppermint oil
with placebo or no treatment. Participants were
required to be followedup for at least one week, and
studies had to report either a global assessment of cure
orimprovementofsymptoms,orcureorimprovement
ofabdominalpain,aftertreatment.Thiswaspreferably
asreportedbythepatient,butcouldbedocumentedby
a doctor. If studies included patients with other
functionalgastrointestinaldisorders,thenweexcluded
these patients from our analyses if trial reporting
allowedthis,butifthiswasnotpossibleweexcludedthe
studies from the meta-analysis. We also considered as
eligible for inclusion the first period of cross over
randomised controlled trials. To allow steady state
plasma concentrations of the agents to be achieved we
considered one week as the minimum duration of
treatment.
We identified studies on irritable bowel syndrome
using the terms “irritable bowel syndrome” and
“functional diseases, colon” (both as medical subject
heading and free text terms), and “IBS, spastic colon,
irritable colon”, and “functional adj5 bowel” (as free
text terms). These were combined using the set
operator AND with studies identified with the terms:
“dietary fibre”, “cereals”, “psyllium”, “sterculia”,
“karaya gum”, “parasympatholytics”, “scopolamine”,
“trimebutine”, “muscarinic antagonists”, “butylscopo-
lammonium bromide” (both as medical subject head-
ings and free text terms), and the following free text
terms: “bulking agent”, “psyllium fibre”, “fibre”,
“husk”, “bran”, “ispaghula”, “wheat bran”, “spasmo-
lytics”, “spasmolytic agents”, “antispasmodics”,
“mebeverine”, “alverine”, “pinaverium bromide”,
“otilonium bromide”, “cimetropium bromide”,
“hyoscine butyl bromide”, “butylscopolamine”, “pep-
permint oil”, and “colpermin”.
No language restrictions were applied. The lead
reviewerevaluatedtheabstractsofpapersidentifiedby
the initial search for appropriateness to the study
question. Potentially relevant papers were obtained
and evaluated in detail. Foreign language papers were
translated when required. We hand searched abstract
books of conference proceedings between 2001 and
2007 to identify potentially eligible studies. The
reference lists of all identified relevant studies were
used to carry out a recursive search of the literature.
Two reviewers independently assessed articles using
predesigned eligibility forms, according to eligibility
criteria defined prospectively. Any disagreement
between investigators was resolved by consensus.
Outcome assessment
The primary outcomes assessed were the efficacy of
fibre, antispasmodics, and peppermint oil compared
with placebo or no treatment on global symptoms of
irritable bowel syndrome or abdominal pain after
treatment. Secondary outcomes included efficacy
according to specific type of fibre or antispasmodic,
and adverse events as a result of treatment.
Data extraction
Two reviewers independently extracted data on to an
Excel spreadsheet (XP professional; Microsoft, Red-
mond, WA) as dichotomous outcomes (persistent or
unimproved global symptoms of irritable bowel
syndrome, or persistent or unimproved abdominal
pain). In addition we extracted the following clinical
data for each trial: setting (primary, secondary, or
tertiary care), number of centres, country, dose and
duration of treatment, total number of adverse events
Excluded (title and abstract
revealed not appropriate) (n=514)
Excluded (n=66):
  No placebo arm (n=33)
  Cross over study with no extractable data (n=8)
  Outcome of interest not reported (n=8)
  Duplicate publication (n=5)
  Not intervention of interest (n=4)
  Included patients with organic gastrointestinal
    disease (n=2)
  Included patients with other functional
    gastrointestinal disorders, not extractable (n=2)
  Treatment duration less than 7 days (n=2) 
  Not randomised (n=1)
  Included patients treated for irritable bowel
    syndrome in remission before trial started (n=1)
Studies eligible for inclusion (n=35):
  Antispasmodics (n=19)
  Fibre (n=9)
  Antispasmodics or  fibre (n=3)
  Peppermint oil (n=4)
Studies identified in literature search (n=615)
Studies retrieved for evaluation (n=101)
Fig 1 | Flow diagram of studies in systematic review
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ment in symptoms or cure after treatment, method of
generation of the randomisation schedule, method for
allocation concealment, level of blinding, proportion
offemalepatients,subtypeofirritablebowelsyndrome
according to predominant stool pattern, and duration
of follow-up. Data were extracted as intention to treat
analyses where all dropouts are assumed to be
treatment failures, whenever this was allowed by trial
reporting. If this was not clear from the original article
then we carried out an analysis on all patients with
reported evaluable data.
Study quality
Two reviewers independently assessed study quality
according to the Jadad scale.
25 This records whether a
studyisdescribedasrandomisedanddoubleblind,the
methods for generation of the allocation schedule and
double blinding, and whether there is a description of
dropouts during the trial.
Data synthesis and statistical analysis
Wepooleddatausingarandomeffectsmodeltogivea
more conservative estimate of the effect of individual
treatments, allowing for any heterogeneity between
studies.
26 The effects of different interventions were
expressedasarelativerisk(95%confidenceinterval)of
global symptoms of irritable bowel syndrome or
abdominal pain persisting with fibre, antispasmodics,
or peppermint oil compared with placebo or no
treatment. For rare outcomes, such as adverse events,
whennopatientsinoneorbothtreatmentarmshadthe
outcomeofinterestinasinglestudy,weadded0.5toall
four cells for the purposes of the analysis. From the
reciprocalofthe riskdifference fromthemeta-analysis
we calculated the number needed to treat and 95%
confidenceintervals.WeusedtheI
2statistic,withacut-
off point of 25%,
27 to assess heterogeneity between
studies and the χ
2 test with a P value <0.10 to define a
significant degree of heterogeneity. We planned to do
sensitivityanalysesaprioriaccordingtotypeoffibreor
antispasmodic, predominant stool pattern of patients,
and study quality according to the Jadad scale. If
adverseeventswerestatisticallysignificantlyincreased
withactivetreatmentwecalculatedthenumberneeded
to harm and a 95% confidence interval using the
formula: number needed to harm=1/(1–relative risk)
× control adverse event rate.
We used Review Manager version 4.2.8 (Nordic
Cochrane Centre, Copenhagen, Denmark) and Stats-
Directversion2.4.4(Sale,Cheshire,England)togenerate
forestplotsofpooledrelativerisksandriskdifferencesfor
primary and secondary outcomes with 95% confidence
intervals. We used the Egger and Begg tests to assess
funnel plots for evidence of publication bias.
28
RESULTS
The search strategy generated 615 citations, of which
101 were potentially relevant and retrieved for
assessment (fig 1). Of these, 66 were excluded for
various reasons, leaving 35 eligible randomised
Table 1 |Characteristics of randomised controlled trials of fibre versus placebo or no treatment in irritable bowel syndrome
Study Country Setting
Diagnostic criteria for
irritable bowel syndrome
Criteria to define symptom
improvement after therapy
Sample
size Fibre type
Duration of
therapy Jadad score
Soltoft 1976
w2 Denmark Tertiary care Clinical diagnosis and
investigations
Patient reported improvement in
global symptoms
59 Miller’sbran30gper
day
6w e e k s 4
Manning
1977
w3
England Tertiary care Clinical diagnosis and
investigations
Any decrease in patient reported
percentage of days with pain
26 Bran 20 g per day
(wheat bran or
whole wheat bread)
6w e e k s 3
Ritchie1979
w33 England Tertiary care Clinical diagnosis and
investigations
Patient reported improvement in
global symptoms (doctor required
to agree)
24 Ispaghula husk two
sachets per day
3 months 4
Longstreth
1981
w9
USA Secondary
care
Clinical diagnosis Patient reported improvement in
global symptoms
77 Metamucil 6.4 g per
day
8w e e k s 4
Arthurs 1983
w8 Ireland Secondary
care
Clinical diagnosis Doctor reported improvement in
global symptoms
78 Ispaghula husk two
sachets per day
4w e e k s 4
Nigam 1984
w35 India Secondary
care
Clinical diagnosis and
investigations
Patient reported improvement in
global symptoms (doctor required
to agree)
42 Ispaghula husk
(dose unclear)
12 weeks 3
Kruis 1986
w34 Germany Tertiary care Clinical diagnosis and
investigations
Patient reported improvement in
global symptoms
80 Wheat bran 15 g per
day
16 weeks 2
Lucey 1987
w7 England Tertiary care Manning criteria and
investigations
Any decrease in global symptom
score
28 Wheat bran biscuits
15.6 g per day
3 months 3
Prior 1987
w6 England Tertiary care Clinical diagnosis and
investigations
Patient reported absence of
abdominal pain
80 Ispaghula husk
three sachets per
day
12 weeks 4
Jalihal 1990
w5 India Secondary
care
Clinical diagnosis and
investigations
Patient reported improvement in
global symptoms
20 Ispaghula husk 30 g
per day
4w e e k s 4
Fowlie 1992
w4 Scotland Tertiary care Clinical diagnosis and
investigations
Patient reported improvement in
global symptoms
49 4.1 g of unspecified
fibre per day
12 weeks 4
Rees 2005
w1 England Tertiary care Rome I criteria and
investigations
Patient reported improvement in
global symptoms
28 Wheat bran 10 to
20 g per day
12 weeks 1
RESEARCH
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no treatment,
w1-w9 19 compared antispasmodics with
placebo,
w10-w28 four compared peppermint oil with
placebo,
w29-w32 and three compared both fibre and
antispasmodics with placebo.
w33-w35
Fibre
Twelve trials compared fibre with placebo or, in one
instance, a low fibre diet,
w3 totalling 591 patients with
irritablebowelsyndrome.
w1-w9 w33-w35Theproportionof
women in the trials ranged between 20% and 90%.
Only three studies reported on subtype of irritable
bowel syndrome according to predominant stool
pattern.
w1 w4 w6 Two recruited only patients with pre-
dominant constipation,
w1 w4 and in the other trial 49%
of patients had predominant constipation.
w6 Table 1
shows the characteristics of the studies. Five studies
used bran,
w1-w3 w7 w34 six used ispaghula husk,
w5 w6 w8 w9
w33 w35 and one used “concentrated” fibre of an
unspecified type.
w4 Seven of the studies scored 4 or
more on the Jadad scale.
w2 w4-w6 w8 w9 w33 None reported
the method of allocation concealment.
Overall, 155 of 300 (52%) patients assigned to fibre
had persistent or unimproved symptoms after treat-
ment compared with 168 of 291 (57%) allocated to
placebo or a low fibre diet (relative risk 0.87, 95%
confidence interval 0.76 to 1.00, P=0.05), with no
statisticallysignificant heterogeneity detectedbetween
studies (I
2=14.2%, P=0.31; fig 2). The number needed
totreatwithfibretopreventonepatientwithpersistent
symptoms was 11 (95% confidence interval 5 to 100).
The funnel plot showed no statistically significant
asymmetry (Egger test, P=0.84), suggesting no evi-
denceofpublicationbias.Whenonlythesevenstudies
scoring4ormoreontheJadadscalewereconsideredin
theanalysisthetreatmenteffectforfibrewasnolonger
statistically significant (relative risk of persistent
symptoms 0.90, 0.75 to 1.08).
w2 w4-w6 w8 w9 w33
Bran
Fivestudiescomparedbranwithplacebooralowfibre
diet in a total of 221 patients.
w1-w3 w7 w34 Only one study
scored4ormoreontheJadadscale.
w2Sixtytwoof114
(54%) patients assigned to bran had persistent
Bran
  Soltoft 1976w2
  Manning 1977w3
  Kruis 1986
w34
  Lucey 1987
w7
  Rees 2005
w1
Subtotal (95% CI)
Test for heterogeneity: χ2=0.99, df=4, P=0.91, I
2=0%
Test for overall effect: z=0.16, P=0.88
Ispaghula
  Ritchie 1979w33
  Longstreth 1981
w9
  Arthurs 1983w8
  Nigam 1984w35
  Prior 1987w6
  Jalihal 1990w5
Subtotal (95% CI)
Test for heterogeneity: χ2=7.63, df=5, P=0.18, I
2=34.4%
Test for overall effect: z=2.31, P=0.02
Fibre (unspecified)
  Fowlie 1992
w4
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z=0.79, P=0.43
Total (95% CI)
Total events: 155 (treatment), 168 (control)
Test for heterogeneity: χ2=12.82, df=11, P=0.31, I2=14.2%
Test for overall effect: z=1.93, P=0.05
1.20 (0.70 to 2.04)
0.86 (0.42 to 1.74)
1.04 (0.78 to 1.37)
0.75 (0.20 to 2.75)
0.86 (0.39 to 1.91)
1.02 (0.82 to 1.27)
0.58 (0.36 to 0.94)
1.15 (0.69 to 1.92)
0.75 (0.39 to 1.43)
0.62 (0.44 to 0.87)
0.89 (0.75 to 1.05)
0.55 (0.11 to 2.59)
0.78 (0.63 to 0.96)
1.37 (0.62 to 3.01)
1.37 (0.62 to 3.01)
0.87 (0.76 to 1.00)
6.19
3.65
17.86
1.13
2.91
31.75
7.50
6.56
4.26
13.54
32.59
0.80
65.24
3.00
3.00
100.00
-0.1 -0.2 -0.5 0 2 5 10
Subcategory and study
Favours
treatment
Favours
control
Relative risk
(random) (95% CI)
Relative risk
(random) (95% CI)
Weight
(%)
17/32
7/14
29/40
3/14
6/14
114
7/12
17/37
11/40
13/21
33/40
2/11
161
10/25
25
300
Treatment
group
12/27
7/12
28/40
4/14
7/14
107
12/12
16/40
14/38
21/21
37/40
3/9
160
7/24
24
291
Control
group
No with symptoms or
abdominal pain/No in group
Fig 2 | Forest plot of randomised controlled trials of fibre versus placebo or low fibre diet in irritable bowel syndrome. Events are
number of patients with either global symptoms of irritable bowel syndrome or abdominal pain unimproved or persistent after
treatment
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(54%)allocatedtoplacebooralowfibrediet.Branhad
no significant effect on irritable bowel syndrome
(relative risk of persistent or unimproved symptoms
1.02,0.82to1.27;fig2),withnostatisticallysignificant
heterogeneity detected between studies (I
2=0%,
P=0.91), and no evidence of funnel plot asymmetry
(Egger test, P=0.28).
Ispaghula
Six studies randomised 321 patients to ispaghula or
placebo.
w5 w6 w8 w9 w33 w35 Eighty three of 161 (52%)
patients allocated to ispaghula had persistent
symptoms after treatment compared with 103 of 160
(64%) receiving placebo. Ispaghula was effective in
treating irritable bowel syndrome (relative risk of
persistentorunimprovedsymptoms0.78,0.63to0.96;
fig 2), with statistically significant heterogeneity
detected between studies (I
2=34.4%, P=0.18). The
number needed to treat with ispaghula to prevent one
patienthavingpersistentsymptomswas6(3to50).No
evidence of funnel plot asymmetry was found (Egger
test, P=0.43). Five of the six studies using ispaghula
scored4ormore onthe Jadadscale.
w5 w6 w8 w9 w33When
only these studies were considered in the analysis the
treatmenteffectforispaghulawasnolongerstatistically
Table 2 |Characteristics of randomised controlled trials of antispasmodics versus placebo or no treatment in irritable bowel syndrome
Study Country Setting
Diagnostic criteria
for irritable bowel
syndrome
Criteria to define symptom
improvement after therapy
Sample
size Antispasmodic and dose
Duration
oftherapy
Jadad
score
Levy 1977
w22 France Secondary care Clinical diagnosis
and investigations
Improvement in global symptoms
(unclear whether patient reported)
50 Pinaverium 50 mg three
times daily
15 days 3
Moshal 1979
w15 South
Africa
Tertiary care Clinical diagnosis
and investigations
Patient reported improvement in
abdominal pain
20 Trimebutine 200 mg three
times daily
4w e e k s 4
Piai 1979
w19 Italy Tertiary care Clinical diagnosis
and investigations
Physicianreportedimprovementinglobal
symptoms
18 Prifinium bromide 30 mg
three times daily
3w e e k s 4
Ritchie 1979
w33 England Tertiary care Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms (doctor required to agree)
24 Hyoscine 10 mg four times
daily
3 months 4
D’Arienzo
1980
w23
Italy Tertiary care Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms
28 Otilonium20mgthreetimes
daily
4w e e k s 3
Fielding 1980
w20 Ireland Secondary care Clinical diagnosis
and investigations
Physicianreportedimprovementinglobal
symptoms
60 Trimebutine 200 mg three
times daily
6 months 3
Delmont 1981
w27 France Secondary care Clinical diagnosis
and investigations
Physicianreportedimprovementinglobal
symptoms
60 Pinaverium (dose unclear)
one tablet three times daily
30 days 4
Page 1981
w21 Unclear Primary and
secondary care
Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms
97 Dicycloverine (dicyclomine)
40 mg four times daily
2w e e k s 4
Baldi 1983
w25 Italy Secondary care Clinical diagnosis
and investigations
Decrease in patient reported abdominal
pain score
30 Otilonium40mgthreetimes
daily
4w e e k s 4
Nigam 1984
w35 India Secondary care Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms (doctor required to agree)
42 Hyoscine (dose unclear) 12 weeks 3
Ghidini 1986
w14 Italy Secondary care Clinical diagnosis
and investigations
Patient reported efficacy of treatment 90 Trimebutine 100 mg three
times daily or rociverine
20 mg three times daily
60 days 3
Kruis 1986
w34 Germany Tertiary care Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms
80 Mebeverine 100 mg four
times daily
16 weeks 4
Virat 1987
w24 France Secondary care Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms
78 Pinaverium 50 mg three
times daily
1w e e k 2
Centonze
1988
w11
Italy Tertiary care Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms
48 Cimetropium 50 mg three
times daily
6 months 4
Gilvarry 1989
w17 Ireland Secondary care Clinical diagnosis
and investigations
Doctor reported improvement in global
symptoms
24 Pirenzipine 50 mg twice
daily
4w e e k s 4
Passaretti
1989
w13
Italy Tertiary care Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms
40 Cimetropium 50 mg three
times daily
1 month 4
Dobrilla 1990
w12 Italy Secondary care Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms
70 Cimetropium 50 mg three
times daily
3 months 4
Schafer 1990
w10 Germany Primary and
secondary care
Clinical diagnosis
and investigations
Improvement in global symptoms
assessed by diary cards
360 Hyoscine 10 mg three times
daily
4w e e k s 3
Castiglione
1991
w26
Italy Tertiary care Clinical diagnosis Improvement in global symptoms
(unclear whether patient reported)
60 Otilonium (dose and
number of tablets unclear)
1 month 2
Pulpeiro 2000
w28 Argentina Tertiary care Clinical diagnosis
and investigations
Patient reported improvement in global
symptoms
75 Propinox (dose and number
of tablets unclear)
4w e e k s 3
Glende 2002
w16 Italy Secondary and
tertiary care
Rome I criteria Decrease in patient reported symptoms
(evaluated on a 4 point ordinal scale) of
one unit in at least one symptom for at
least two weeks
317 Otilonium40mgthreetimes
daily
15 weeks 3
Mitchell 2002
w18 UK Secondary and
tertiary care
Rome II criteria and
investigations
Improvement in wellbeing from validated
diary cards
107 Alverine120 mgthree times
daily
12 weeks 5
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 5 of 11Cimetropium
  Centonze 1988w11
  Passaretti 1989
w13
  Dobrilla 1990w12
Subtotal (95% CI)
Hyoscine
  Ritchie 1979
w33
  Nigam 1984w35
  Schafer 1990w10
Subtotal (95% CI)
Pinaverium
  Levy 1977w22
  Delmont 1981
w27
  Viral 1987w24
Subtotal (95% CI)
Trimebutine
  Moshal 1979w15
  Fielding 1980
w20
  Ghidini 1986
w14
Subtotal (95% CI)
Mebeverine
  Kruis 1986w34
Subtotal (95% CI)
Otilonium
  D’Arienzo 1980w23
  Baldi 1983
w25
  Castiglione 1991w26
  Glende 2002w16
Subtotal (95% CI)
Alverine
  Mitchell 2002w18
Subtotal (95% CI)
Dicycloverine (dicyclomine)
  Page 1981w21
Subtotal (95% CI)
Pirenzipine
  Gilvarry 1989w17
Subtotal (95% CI)
Prifinium
  Piai 1979w19
Subtotal (95% CI)
Propinox
  Pulpeiro 2000w28
Subtotal (95% CI)
Rociverine
  Ghidini 1986w14
Subtotal (95% CI)
Total (95% CI)
Total events: 350 (treatment), 495 (control)
0.21 (0.08 to 0.53)
0.58 (0.29 to 1.17)
0.36 (0.13 to 1.03)
0.38 (0.20 to 0.71)
0.67 (0.45 to 0.99)
0.52 (0.35 to 0.79)
0.67 (0.49 to 0.93)
0.63 (0.51 to 0.78)
0.33 (0.16 to 0.70)
0.46 (0.20 to 1.05)
0.54 (0.34 to 0.87)
0.47 (0.33 to 0.67)
0.75 (0.22 to 2.52)
1.31 (0.78 to 2.19)
0.80 (0.37 to 1.74)
1.08 (0.72 to 1.61)
1.25 (0.99 to 1.58)
1.25 (0.99 to 1.58)
0.25 (0.03 to 1.97)
0.43 (0.14 to 1.35)
0.40 (0.21 to 0.76)
0.81 (0.70 to 0.94)
0.55 (0.31 to 0.97)
0.85 (0.60 to 1.22)
0.85 (0.60 to 1.22)
0.65 (0.45 to 0.95)
0.65 (0.45 to 0.95)
1.17 (0.56 to 2.45)
1.17 (0.56 to 2.45)
0.50 (0.18 to 1.40)
0.50 (0.18 to 1.40)
1.23 (0.30 to 5.13)
1.23 (0.30 to 5.13)
1.10 (0.55 to 2.19)
1.10 (0.55 to 2.19)
0.68 (0.57 to 0.81)
2.72
3.89
2.25
8.87
6.38
6.31
7.17
19.86
3.62
3.15
5.66
12.44
1.78
5.29
3.39
10.46
8.06
8.06
0.70
1.95
4.24
8.79
15.68
6.82
6.82
6.64
6.64
3.61
3.61
2.29
2.29
1.36
1.36
3.93
3.93
100.00
-0.1 -0.2 -0.5 0 2 5 10
Subcategory and study
Favours
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Fig 3 | Forest plot of randomised controlled trials of antispasmodics versus placebo in treatment of irritable bowel syndrome.
Events are number of patients with either global symptoms of irritable bowel syndrome or abdominal pain unimproved or
persistent after treatment. See bmj.com for individual tests for heterogeneity and for overall effect
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symptoms 0.86, 0.74 to 1.01, P=0.06), with no
statisticallysignificant heterogeneity detectedbetween
studies (I
2=2.6%, P=0.39).
Adverse events
Data on the total number of adverse events were
provided by only four trials.
w4 w6 w34 w35 These trials
evaluated 251 patients, but as the number of adverse
events was small the data were not pooled. A total of
three patients receiving fibre reported adverse events
compared with two in the placebo arms.
Antispasmodics
Twenty two studies compared 12 different anti-
spasmodics with placebo in 1778 patients.
w10-w28 w33-w35
The proportion of women in each trial ranged from
39%to83%.Sixstudiesreportedonsubtypeofirritable
bowel syndrome according to predominant stool
pattern.
w11 w12 w14 w15 w19 w24Onestudyrecruitedpatients
only with predominant constipation,
w15 and in the
remaining five studies between 22% and 64% of
patients had predominant constipation. Table 2
shows the characteristics of the studies. None of the
trials reported the method of allocation concealment.
Four trials used otilonium,
w16 w23 w25 w26 three cimetro-
pium,
w11-w13 three hyoscine,
w10 w33 w35 three pinaver-
ium,
w22 w24 w27 two trimebutine,
w15 w20 one trimebutine
and rociverine,
w14 and one each of alverine,
w18 dicy-
cloverine (dicyclomine),
w21 mebeverine,
w34 pirenzipi-
ne,
w17 prifinium,
w19 and propinox.
w28
In total, 350 of 905 (39%) patients assigned to
antispasmodics had persistent symptoms after treat-
ment compared with 485 of 873 (56%) allocated to
placebo (relative risk 0.68, 95% confidence interval
0.57to0.81),withstatisticallysignificantheterogeneity
detected between studies (I
2=62.6%, P<0.001; fig 3).
The number needed to treat to prevent symptoms
persistinginonepatientwas5(95%confidenceinterval
4to9).TheEggertestsuggestedevidenceoffunnelplot
asymmetry(P=0.03),but thisseemed to be driven by a
single small study; the Begg test did not confirm
asymmetry (P=0.25). The treatment effect in favour of
antispasmodics remained when only the 12 trials that
scored4ormoreontheJadadscalewereconsideredin
the analysis (relative risk of persistent symptoms 0.65,
0.48 to 0.89),
w11-w13 w15 w17-w19 w21 w25 w27 w33 w34 although
theheterogeneityobservedbetweenstudies(I
2=70.2%,
P=0.0001) persisted and there was evidence of
publication bias (Egger test, P=0.007).
The effect of different antispasmodics on symptoms
of irritable bowel syndrome was examined separately.
Four trials used otilonium in 435 patients.
w16 w23 w25 w26
Symptoms persisted in 111 of 216 (51%) patients
assignedtootiloniumcomparedwith155of219(71%)
of those receiving placebo (relative risk 0.55, 0.31 to
0.97, I
2=59.5%), and a number needed to treat of 4.5
(95%confidenceinterval3.0 to10.0).Threetrialsused
cimetropium,
w11-w13 with 15 of 79 (19%) patients
randomised to cimetropium having persistent symp-
toms after treatment compared with 42 of 79 (53%)
receiving placebo (relative risk 0.38, 0.20 to 0.71,
I
2=37.2%). The number needed to treat with cimetro-
pium was 3.0 (2.0 to 12.5). Three studies randomised
426 patients to hyoscine or placebo.
w10 w33 w35 Symp-
toms persisted in 63 of 215 (29%) patients receiving
hyoscine compared with 97 of 211 (46%) allocated to
placebo (relative risk 0.63, 0.51 to 0.78, I
2=0%), with a
numberneededtotreatof3.5(2.0to25.0).Threetrials
used pinaverium in 188 patients.
w22 w24 w27 Symptoms
persisted in 26 of 94 (28%) patients assigned to
pinaverium compared with 57 of 94 (61%) receiving
placebo (relative risk 0.47, 0.33 to 0.67, I
2=0%), and a
number needed to treat of 3 (2 to 5). Three trials,
totalling 140 patients, studied the effect of trimebuti-
ne.
w14 w15 w20Twentyeightof70(40%)patientsassigned
to trimebutine had persistent symptoms compared
with 27 of 70 (39%) allocated to placebo (relative risk
1.08,0.72to1.61,I
2=0%).Therelativeriskofpersistent
symptoms in the single trials that used other anti-
spasmodics were: mebeverine 1.25 (0.99 to 1.58),
alverine0.85(0.60to1.22),dicycloverine0.65(0.45to
0.95), pirenzipine 1.17 (0.56 to 2.45), prifinium 0.50
(0.18 to 1.40), propinox 1.23 (0.30 to 5.13), and
rociverine 1.10 (0.55 to 2.19).
Adverse events
Thirteen studies reported a total number of adverse
events in 1379 patients.
w10-w16 w18 w20 w21 w25 w27 w34 Over-
all, 101 of 704 (14%) patients assigned to anti-
spasmodics experienced adverse events compared
with 62 of 675 (9%) allocated to placebo. The
Table 3 |Characteristics of randomised controlled trials of peppermint oil versus placebo in irritable bowel syndrome
Study Country Setting
Diagnostic criteria for
irritable bowel syndrome
Criteria to define symptom
improvement after therapy
Sample
size
Dose of
peppermint oil
Duration of
therapy Jadad score
Lech 1988
w29 Denmark Secondary care Clinical diagnosis and
investigations
Patient reported improvement in global
symptoms
47 200 mg three
times daily
4w e e k s 3
Liu 1997
w30 Taiwan Secondary care Clinical diagnosis and
investigations
Patient reported improvement in
abdominal pain
110 187 mg three or
four times daily
1 month 4
Capanni
2005
w32
Italy Secondary care Rome II Improvement in global symptoms
assessed by validated questionnaire
178 2 capsules three
times daily
3 months 5
Cappello
2007
w31
Italy Secondary care Rome II and investigations ≥50% improvement from baseline in
overallirritablebowelsyndromesymptom
score using questionnaire data
57 225 mg twice
daily
4w e e k s 5
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and blurred vision, but none of the trials reported any
serious adverse events. The relative risk of experien-
cing adverse events with antispasmodics compared
withplacebowas1.62(95%confidenceinterval1.05to
2.50), with statistically significant heterogeneity
detected between studies (I
2=37.9%, P=0.07), but no
evidence of publication bias (Egger test, P=0.53). The
number needed to harm with antispasmodics was 17.5
(7.0 to 217.0).
Peppermint oil
Four studiescomparedpeppermintoil withplaceboin
392 patients.
w29-w32 The proportion of women in each
trialrangedfrom40%to76%.Onlyonestudyreported
on disease subtype according to stool pattern and
recruited 25% of patients with predominant constipa-
tion and 75% with predominant diarrhoea.
w31 Table 3
shows the characteristics of the studies. None of the
trials reported the method of allocation concealment.
Fifty two of 197 (26%) patients randomised to
peppermint oil had persistent symptoms compared
with 127 of 195 (65%) receiving placebo (relative risk
0.43, 0.32 to 0.59; fig 4), with statistically significant
heterogeneity detected between studies (I
2=31.1%,
P=0.23). The number needed to treat with peppermint
oil to prevent one patient having persistent symptoms
was 2.5 (2.0 to 3.0). When only the three studies that
scored4ormoreontheJadadscalewereconsideredin
theanalysistherelativeriskofpersistentsymptomswas
of a similar magnitude (0.40, 0.29 to 0.55), with no
statisticallysignificant heterogeneity detectedbetween
studies (I
2=22.0%, P=0.28).
w30-w32
Adverse events
Onlythreestudiesreporteddataonadverseevents,
w30-
w32 and as these were few in number the data were not
pooled. Five adverse events occurred among 174
patients assigned to peppermint oil compared with no
adverse events in 171 patients receiving placebo.
DISCUSSION
This systematic review and meta-analysis has shown
that fibre, antispasmodics, and peppermint oil are all
moreeffectivethanplacebointhetreatmentofirritable
bowel syndrome. The number needed to treat to
preventonepatienthavingpersistentsymptomswas11
for fibre, 5 for antispasmodics, and 2.5 for peppermint
oil.Adverseeventsweresignificantlymorefrequentin
those receiving antispasmodics than in those receiving
placebo, but none of these was serious. As several
different treatments were studied in the included
randomised controlled trials, we carried out subgroup
analyses.
Whentypeoffibrewasexamined,wheatbranwasno
more effective at treating irritable bowel syndrome
thanplacebooralowfibrediet.Thebeneficialeffectof
fibre seemed to be limited to ispaghula husk, with a
number needed to treat of 6 compared with placebo.
However, significant heterogeneity was detected
between trials. When only high quality studies were
considered in the analysis this heterogeneity was
diminished, but the difference in effect on symptoms
in favour of ispaghula husk only reached marginal
statistical significance.
Antispasmodics were of benefit, but again hetero-
geneitybetweenstudyresultswassignificant,andthere
wasevidenceofpublicationbias.Datawerelimitedfor
many of the drugs licensed for use in the United
Kingdom, such as mebeverine, dicycloverine, and
alverine.Itisdifficulttoknowwhetherthisisatrueclass
effect of antispasmodics. Of all the drugsstudied, most
data were available for otilonium, trimebutine, cime-
tropium, hyoscine, and pinaverium. Trimebutine
seemed to have no benefit over placebo in treating
irritablebowelsyndrome,whereastheotherfourdrugs
allsignificantlyreducedtheriskofpersistentsymptoms
aftertreatment.Considerable heterogeneity was,how-
ever, detected between individual trials using otilo-
nium and cimetropium and, although this was not the
case when studies of pinaverium were pooled, the
number of included patients was small. The best
evidence for an individual compound seems to be for
  Lech 1988
w29
  Liu 1997
w30
  Capanni 2005
w32
  Cappello 2007
w31
Total (95% CI)
Total events: 52 (treatment), 127 (control)
Test for heterogeneity: χ2=4.36, df=3, P=0.23, I2=31.1%
Test for overall effect: z=5.39, P<0.001
0.58 (0.34 to 0.98)
0.41 (0.25 to 0.68)
0.31 (0.20 to 0.48)
0.55 (0.31 to 0.96)
0.43 (0.32 to 0.59)
23.82
25.33
29.58
21.27
100.00
-0.1 -0.2 -0.5 0 2 5 10
Study
Favours
treatment
Favours
control
Relative risk
(random) (95% CI)
Relative risk
(random) (95% CI)
Weight
(%)
10/23
14/55
18/91
10/28
197
Treatment
group
18/24
34/55
56/87
19/29
195
Control
group
No with symptoms or
abdominal pain/No in group
Fig 4 | Forestplotofrandomisedcontrolledtrialsofpeppermintoil versusplaceboinirritable bowelsyndrome.Eventsare number
of patients with either global symptoms of irritable bowel syndrome or abdominal pain unimproved or persistent after treatment
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patients. No statistically significant heterogeneity was
detected, and 3.5 patients would need to be treated to
prevent symptoms persisting in one patient. It would
seem reasonable for general practitioners who want to
begin a trial of antispasmodics to use hyoscine as first
line treatment, but to consider other antispasmodics
when this strategy fails.
Peppermint oil was also superior to placebo,
although statistically significant heterogeneity was
detected between study results, and only four rando-
mised controlled trials were identified including fewer
than 400 patients, so data were more limited than for
fibre and antispasmodics. Three of these trials scored
morethan4ontheJadadscale,
w30-w32butthetreatment
effect was similar when only these studies were
included in the meta-analysis, and the heterogeneity
observed between studies was no longer detected.
Thereportinginthissystematicreviewadherestothe
quality of reporting of meta-analyses statement.
29 We
have also specified the search strategy used, as well as
our data extraction criteria. We believe that stating the
criteria for data extraction should be standard in all
systematic reviews that pool dichotomous data. The
combinationofourcomprehensivesearchstrategyand
thetranslationofforeignlanguagearticlesenabledusto
identify studies with data from over 2500 people with
irritable bowel syndrome.
Limitationsofthecurrentstudyarisefromthequality
ofthestudieseligibleforinclusion,whichinmostcases
was moderate to good, according to the Jadad scale.
None of the included randomised controlled trials
reported the method of allocation concealment, how-
ever, and as this has been shown to exaggerate
treatment effect
30 the numbers needed to treat with
these treatments may have been overestimated. Most
trialsweredonebeforetheRomecommitteepublished
their recommendations for the design of randomised
controlled trials of therapies in functional gastro-
intestinal disorders.
31 Only five of the included studies
used the Rome criteria to define the presence of
irritablebowelsyndrome,
w1 w16 w18 w31 w32althoughonly
nine were published after the first Rome classification
was proposed in 1990,
w1 w4 w16 w18 w26 w28 w30-w32 and only
two used a validated outcome measure to define
improvement in symptoms after treatment.
w18 w32
However, many of the included trials met some of the
other suggested methodological criteria, such as
presence of double blinding and a minimum duration
oftherapyof8to12weeks.Wepreferentiallyextracted
patientreportedimprovementinsymptomsofirritable
bowel syndrome or abdominal pain whenever trial
reporting allowed this, which is also in line with these
recommendations.Blindingofpatientsinthesestudies
may not have been entirely successful owing to
differences in consistency and texture between fibre
and placebo, adverse events experienced with anti-
spasmodicsand,inthecaseofpeppermintoil,thesmell
and taste of active treatment.The pooling of data from
trials to give an overall treatment effect, and a number
neededtotreat,couldbecriticisedbysomeasaresultof
differences in the methodology of individual included
studies. We carried out sensitivity analyses to explore
reasons for heterogeneity between studies and in all
cases identified potential reasons for this, while still
showing a significant treatment effect for most of the
treatments we assessed.
Several previous systematic reviews have examined
the role of these three treatments in irritable bowel
syndrome.
15-22 All of these, however, have limitations.
Three reviews did not synthesise data, so no summary
effectofindividualtreatmentswasreported.
15-17Ofthe
fivethatextractedandpooleddatainameta-analysisall
have numerous methodological errors,
18-22 which
render their findings potentially inaccurate. These
includeerrorsintheextractionofdichotomousdatain
a large proportion of included randomised controlled
trials,
18-22inclusionofnon-eligiblestudies(accordingto
theinvestigatorsprespecifiedinclusioncriteria)infour
meta-analyses,
18-2022 incorrect handling of data from
cross over studies,
18192122 failure to carry out an
intention to treat analysis when trial reporting
allowed,
19-22 incorporating studies that included
patients with other functional gastrointestinal diseases
intheanalysis,
1820andfailuretoidentifyeligiblestudies
published at the time of the literature search,
18-2022
leadingtodataontrulyeligiblepatientsbeingexcluded
from the analysis. These errors led to either an
overestimation or underestimation of the pooled
treatment effect in many of these meta-analyses.
19-22
Inaddition,sincethesereviewswerecarriedoutfurther
randomised controlled trials of all these treatments
have been published.
Current guidelines for the management of irritable
bowel syndrome are equivocal or conflicting in
their recommendations for the use of these
treatments,
11122324 b u tm o s to ft h e s eh a v eb e e n
informed by previous systematic reviews, which are
potentially methodologically flawed for the reasons
discussed, and this has implications for the statements
made in them. In the UK, guidelines from both the
National Institute for Health and Clinical Excellence
and the British Society of Gastroenterology provide
similar advice.
1112 Antispasmodics are recommended
WHAT IS ALREADY KNOWN ON THIS TOPIC
Irritablebowelsyndromeisachronic,relapsingandremittingdisorder,whichcanbedifficultto
treat
Safe, effective treatments are required, as newer more expensive therapies have been
withdrawn because of concerns about safety
Fibre, antispasmodics, and peppermint oil may fulfil this role, but evidence for their use is
conflicting owing to methodological errors in previous systematic reviews
WHAT THIS STUDY ADDS
Fibre,antispasmodics(particularlyhyoscineandotilonium),andpeppermintoilwereallmore
effective than placebo for treating irritable bowel syndrome
The numbers needed to treat with these therapies were 11, 5, and 2.5, respectively
Doctors should consider ispaghula, antispasmodics (preferably hyoscine as first line
treatment), and peppermint oil to treat irritable bowel syndrome
RESEARCH
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bloating are the predominant symptoms, although
which of these drugs should be preferred is not stated.
The use of insoluble fibre is discouraged because of
concerns that it may exacerbate symptoms, an
observation not borne out by our findings. Both
organisationsrecommendthatiffibresupplementation
is required then this should be in the form of soluble
fibres such as ispaghula. Finally, neither of these
guidelines provides any statement on the role of
peppermint oil in the management of irritable bowel
syndrome.
The biological rationale for the efficacy of anti-
spasmodics is unclear, but recent research using
magnetic resonance imaging has shown that patients
with irritable bowel syndrome and predominant
diarrhoea have a reduced colon diameter as well as
accelerated small bowel transit,
32 so antispasmodics
may act by reducing colonic contraction and transit
timeandthereforepainandstoolfrequency.Ispaghula
husk may increase transit time in those with irritable
bowel syndrome and predominant constipation. The
efficacy of peppermint oil may arise from effects on
smooth muscle, again reducing colonic contractility
and pain owing to its calcium channel blocking
activity.
14 We were unable to examine the effect of
different treatments according to predominant stool
patternreportedbythepatients,however,becausefew
oftheeligibletrialsreportedthesedataasmanypredate
the use of these subgroups, making it difficult to assign
people to these categories retrospectively.
In summary, this systematic review and meta-
analysis shows that ispaghula husk, antispasmodics
(particularly hyoscine), and peppermint oil are all
effective treatments for irritable bowel syndrome.
Many of these are safe and available over the counter
but, with the advent of newer more expensive drugs,
are often overlooked as potentially effective treat-
ments. Further large trials of these three agents in
patients with irritable bowel syndrome, defined
according to the Rome criteria, and using validated
outcome measures are warranted. In the interim,
current national guidelines for the management of the
condition should be updated to include these data.
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